Open Access
Table 1
Results of IgM detection with Toxo-ISAGA IgM®, Liaison Toxo IgM®, Architect/Alinity Toxo IgM®, Vidas Toxo IgM®, and Platelia Toxo IgM® assays on 1,341 adult sera with negative IgG and positive IgM by at least one test.
| Clinical status | Assay | Number of samples with the following result |
||
|---|---|---|---|---|
| Negative | Equivocal | Positive | ||
| Recent Toxoplasma infection (seroconversion) | Toxo-ISAGA IgM® (n = 156) | 2 (1.3%) | 5 (3.2%) | 149 (95.5%) |
| Liaison Toxo IgM® (n = 96) | 9 (9.4%) | 6 (6.2%) | 81 (84.4%) | |
| Architect/Alinity Toxo IgM® (n = 47) | 2 (4.2%) | 2 (4.2%) | 43 (91.5%) | |
| Vidas Toxo IgM® (n = 11) | 2 (18.2%) | 2 (18.2%) | 7 (63.6%) | |
| Platelia Toxo IgM® (n = 18) | 1 (5.5%) | 1 (5.5%) | 16 (88.9%) | |
| Absence of Toxoplasma infection (nonspecific IgM) | Toxo-ISAGA IgM® (n = 1,185) | 877 (74.0%) | 154 (13.0%) | 154 (13.0%) |
| Liaison Toxo IgM® (n = 788) | 719 (91.2%) | 31 (3.9%) | 38 (4.8%) | |
| Architect/Alinity Toxo IgM® (n = 366) | 221 (60.4%) | 22 (6.0%) | 123 (33.6%) | |
| Vidas Toxo IgM® (n = 67) | 48 (71.6%) | 3 (4.5%) | 16 (23.9%) | |
| Platelia Toxo IgM® (n = 41) | 10 (24.4%) | 1 (2.4%) | 30 (73.2%) | |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.